Common use of SEC Filings and Other Disclosures Clause in Contracts

SEC Filings and Other Disclosures. Either Party may disclose the terms of this Agreement (a) to the extent required, in the reasonable opinion of such Party’s legal counsel, to comply with applicable laws, including, without limitation, the rules and regulations promulgated by the United States Securities and Exchange Commission, the New York Stock Exchange and NASDAQ and (b) in connection with a prospective acquisition, merger or financing for such Party, to prospective acquirers or merger candidates or to existing or potential investors, provided that prior to such disclosure each such candidate or investor shall be agree in writing to be bound by obligations of confidentiality and non-use no less restrictive in scope than those set forth in this Section 8 (Confidentiality). Notwithstanding the foregoing, before disclosing this Agreement or any of the terms hereof pursuant to (a) above, the Parties will consult with one another on the terms of this Agreement to be redacted in making any such disclosure. If a Party discloses this Agreement or any of the terms hereof in accordance with clause (a) above, such Party agrees, at its own expense, to seek such confidential treatment of portions of this Agreement or such terms, as may be reasonably requested by the other Party.

Appears in 1 contract

Samples: Development Agreement (Progenics Pharmaceuticals Inc)

AutoNDA by SimpleDocs

SEC Filings and Other Disclosures. Either Party may disclose the terms of this Agreement (a) and make any other public written disclosure regarding the existence of, or performance under, this Agreement, to the extent required, in the reasonable opinion of such Party’s legal counsel, to comply with (a) applicable lawsLaw, including, without limitation, including the rules and regulations promulgated by the United States Securities and Exchange Commission, the New York Stock Exchange and NASDAQ and Commission or (b) any equivalent Governmental Authority, securities exchange or securities regulator in connection with a prospective acquisition, merger or financing for such Party, to prospective acquirers or merger candidates or to existing or potential investors, provided that prior to such disclosure each such candidate or investor shall be agree any country in writing to be bound by obligations of confidentiality and non-use no less restrictive in scope than those set forth in this Section 8 (Confidentiality)the Territory. Notwithstanding the foregoing, before Before disclosing this Agreement or any of the terms hereof pursuant to (a) abovethis Section 6.3, the Parties will consult with one another on the terms of this Agreement to be redacted in making any such disclosure, with the Party disclosing pursuant to this Section 6.3 providing as much advance notice as is feasible under the circumstances, and giving consideration to the comments of the other Party. If Further, if a Party discloses this Agreement or any of the terms hereof in accordance with clause (a) abovethis Section 6.3, such Party agreeswill, at its own expense, to seek such confidential treatment of confidential portions of this Agreement or and such other terms, as may be reasonably requested by the other PartyParty and limit its disclosure of such Confidential Information to only that required to comply with applicable Law.

Appears in 1 contract

Samples: License Agreement (Theravance Biopharma, Inc.)

SEC Filings and Other Disclosures. Either Party may disclose the terms of this Agreement (a) and make any other public written disclosure regarding the existence of, or performance under, this Agreement, to the extent required, in the reasonable opinion of such Party’s legal counsel, to comply with (a) applicable lawsLaw, including, without limitation, including the rules and regulations promulgated by the United States Securities and Exchange Commission, the New York Stock Exchange and NASDAQ and Commission or (b) any equivalent Governmental Authority, securities exchange or securities regulator in connection with a prospective acquisition, merger or financing for such Party, to prospective acquirers or merger candidates or to existing or potential investors, provided that prior to such disclosure each such candidate or investor shall be agree any country in writing to be bound by obligations of confidentiality and non-use no less restrictive in scope than those set forth in this Section 8 (Confidentiality)the Territory. Notwithstanding the foregoing, before Before disclosing this Agreement or any of the terms hereof pursuant to (a) abovethis Section 11.4, the Parties will consult with one another on the terms of this Agreement to be redacted in making any such disclosure, with the disclosing Party providing as much advance notice as is feasible under the circumstances, and giving consideration to the timely comments of the other Party. If Further, if a Party discloses this Agreement or any of the terms hereof in accordance with clause (a) abovethis Section 11.4, such Party agreeswill, at its own expense, to seek such confidential treatment of confidential portions of this Agreement or and such termsother terms as it reasonably determines, giving consideration to the comments of the other Party pursuant to the preceding sentence. [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as may be reasonably requested by the other Partyamended.

Appears in 1 contract

Samples: Collaboration and License Agreement (Sangamo Therapeutics, Inc)

SEC Filings and Other Disclosures. Either Notwithstanding any provision of this Agreement to the contrary, either Party may disclose the terms of this Agreement (a) to the extent required, in the reasonable opinion of such Party’s legal counsel, to comply with applicable lawsLaw, including, without limitation, including the rules and regulations promulgated by the United States Securities and Exchange Commission, Commission or any equivalent governmental agency in any country in the New York Stock Exchange and NASDAQ and (b) in connection with a prospective acquisition, merger or financing for such Party, to prospective acquirers or merger candidates or to existing or potential investors, provided that prior to such disclosure each such candidate or investor shall be agree in writing to be bound by obligations of confidentiality and non-use no less restrictive in scope than those set forth in this Section 8 (Confidentiality)Territory. Notwithstanding the foregoing, before disclosing this Agreement or any of the terms hereof pursuant to (a) abovethis Section 7.2.3, the Parties will consult with one another on the terms of this Agreement to be redacted in making any such disclosure. If Further, if ***Certain information contained herein has been omitted pursuant to Regulation S-K 601(b)(10). Confidential treatment has been granted with respect to the omitted portions. a Party discloses this Agreement or any of the terms hereof in accordance with clause (a) abovethis Section 7.2.3, such Party agreesshall, at its own expense, use Commercially Reasonable Efforts to seek such confidential treatment of confidential portions of this Agreement or and such other terms, as may be reasonably requested by the other Party.

Appears in 1 contract

Samples: Option and License Agreement (CytomX Therapeutics, Inc.)

AutoNDA by SimpleDocs

SEC Filings and Other Disclosures. Either Party may disclose the terms of this Agreement (a) and make any other public written disclosure regarding the existence of, or performance under, this Agreement, to the extent required, in the reasonable opinion of such Party’s legal counsel, to comply with (a) applicable lawsLaw, including, without limitation, including the rules and regulations promulgated by the United States Securities and Exchange Commission, the New York Stock Exchange and NASDAQ and Commission or (b) any equivalent Governmental Authority, securities exchange or securities regulator in connection with a prospective acquisition, merger or financing for such Party, to prospective acquirers or merger candidates or to existing or potential investors, provided that prior to such disclosure each such candidate or investor shall be agree any country in writing to be bound by obligations of confidentiality and non-use no less restrictive in scope than those set forth in this Section 8 (Confidentiality)the Territory. Notwithstanding the foregoing, before Before disclosing this Agreement or any of the terms hereof pursuant to (a) abovethis Section 7.3, the Parties will consult with one another on the terms of this Agreement to be redacted in making any such disclosure, with the Party disclosing pursuant to this Section 7.3 providing as much advance notice as is feasible under the circumstances, and giving consideration to the comments of the other Party. If Further, if a Party discloses this Agreement or any of the terms hereof in accordance with clause (a) abovethis Section 7.3, such Party agreeswill, at its own expense, to seek such confidential treatment of confidential portions of this Agreement or and such other terms, as may be reasonably requested by the other Party and limit its disclosure of such Confidential Information to only that required to comply with applicable Law as reasonably determined by such disclosing Party.

Appears in 1 contract

Samples: Research Collaboration and License Agreement (Locust Walk Acquisition Corp.)

Time is Money Join Law Insider Premium to draft better contracts faster.